Dalacin vaginal cream with applicator 2% 20g

Packaging

Tuba 20

Mechanism of action

Dalacin - an antibiotic of the group of lincosamides for local use. The mechanism of action is associated with the suppression of protein synthesis in the microbial cell due to the interaction with the 50S-subunit of ribosomes. Has a bacteriostatic effect; in higher concentrations in relation to some microorganisms - bactericidal. The drug is active against microorganisms that cause bacterial vaginosis: Gardnerella vaginalis, Mobiluncus spp., Mycoplasma hominis, Peptostreptococcus spp., Bacteroides spp.

Bacterial vaginosis.

Contraindications

Hypersensitivity to Clindamycin, Lincomycin or any component of the drug Dalacin.

Pregnancy and Breastfeeding

Adequate and controlled studies on the use of the drug in the first trimester of pregnancy has not been conducted.The use of Dalacin in the first trimester of pregnancy is possible only if the intended benefit outweighs the potential risk to the fetus.
When using clindamycin preparations in the II and III trimesters of pregnancy in dosage forms for intravaginal administration, there was no increase in the incidence of congenital anomalies of the fetus. If Dalacin is used in the II and III trimesters of pregnancy (although there have been no official studies on the use of suppositories during pregnancy), then an adverse effect on the fetus seems unlikely.
Currently, there are no data on the excretion of clindamycin in breast milk with intravaginal use of Dalacin. However, it has been established that with the introduction of clindamycin orally or parenterally, a certain amount of it is found in breast milk. Therefore, when deciding on the possibility of prescribing Dalacin during lactation (breastfeeding), it is necessary to compare the expected benefits for the mother and the possible risk for the child.

Dosage and administration

A single dose (1 full applicator (5 g of cream, approximately 100 mg of clindamycin) is injected into the vagina at bedtime for 3 consecutive days. The cream can be injected for 7 consecutive days.

Adverse reactions

The incidence rate listed below is less than 10%.
From the reproductive system:irritation of the mucous membrane of the vulva and vagina, vaginal pain, vaginal discharge, vaginal candidiasis, vulvovaginitis, trichomonas vaginitis, vaginal infections, menstrual disorders, uterine bleeding, abnormal delivery, endometriosis.
On the part of the urinary system: dysuria, urinary tract infections (including pyelonephritis), proteinuria.
Gastrointestinal: generalized abdominal pain, localized abdominal pain, abdominal cramps, bloating, dyspepsia, nausea, vomiting, diarrhea, constipation, flatulence, bad breath, a perversion of taste.
From the side of the central nervous system: dizziness, headache.
Dermatologic:rash, itching, maculo-papular rash, erythema, skin candidiasis.
Allergic reactions:hives.
On the part of the endocrine system: glycosuria, hyperthyroidism.
On the part of the body as a whole:fungal infections, fever, pain in the side, back pain, lower abdominal pain, generalized pain, bacterial infections, inflammatory edema, upper respiratory tract infections, nasal bleeding, deviation of microbiological results from the norm.
Local reactions: itching and pain at the injection site.

Before prescribing the drug with the help of special laboratory methods, the following possible causative agents of vulvovaginitis should be excluded: Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus.
Intravaginal administration of Dalacin can lead to increased growth of microorganisms insensitive to the preparation, especially yeast-like fungi.
With the use of the drug systemic absorption of clindamycin is possible. With systemic use of clindamycin may develop severe diarrhea and in some cases pseudomembranous colitis.In this regard, when severe or prolonged diarrhea occurs during the treatment with Dalacin, it is necessary to discontinue the drug, conduct diagnostic procedures and, if necessary, prescribe appropriate treatment.

An in vitro antagonistic interaction between clindamycin and Erythromycin has been demonstrated.
It has been established that with systemic use, clindamycin disrupts neuromuscular transmission, therefore, it is possible to enhance the effect of muscle relaxants of the peripheral action. This fact should be taken into account when it is necessary to appoint the latter with Dalacin.
In pharmacodynamic, pharmacokinetic or clinical studies of these dosage forms, no interactions were observed.

The drug should be stored out of reach of children at a temperature not exceeding 25 ° C. Do not freeze.